Three independent mutations involving the apoptosis-1 (APO-1)/Fas receptor or its putative ligand have led to lupuslike diseases associated with lymphadenopathy in different strains of mice. To determine whether humans with SLE also have a defect in this apoptosis pathway, we analyzed the expression of APO-1 on freshly isolated blood mononuclear cells and on lymphocytes activated in vitro using flow cytometry and the monoclonal antibody anti-APO-1. Significantly higher levels of APO-1 expression were detected on freshly isolated peripheral B cells and both CD4' and CD8' T lymphocyte populations obtained from lupus patients when compared with normal controls (P < 0.001). Almost 90% of the cells that stained positive for APO-1 also expressed the CD29 antigen, suggesting that APO-1 was upregulated after lymphocyte activation in vivo. No defect in APO-1 regulation was detected after activation of SLE T (with anti-CD3) or B (with Staphylococcus aureus Cowan 1) lymphocytes in the presence of IL-2 in vitro. Similarly, the anti-APO-1 antibody induced apoptosis in 74±5% of activated SLE T cells in vitro compared with 79±6% of the normal controls (P > 0.05). These results reveal that, while APO-1 / Fas may play an important role in the regulation of lymphocyte survival in SLE, no consistent defect in the expression or function of the receptor could be detected in these studies. (J. Clin.
Introduction
Apoptosis-1 (APO-1 )1 is a 48-kD cell-surface glycoprotein that signals certain lymphocytes to die by apoptosis upon ligation with the monoclonal anti-APO-l antibody (1) . APO-l is a member of the nerve growth factor family of receptors that are characterized by an extramembranous segment comprising cysteine-rich domains, a single transmembrane domain, and a cytoplasmic region of various size (2) . Nucleotide sequence analysis ofcDNAs encoding APO-1 (3) and the Fas protein (4) has shown that these proteins are identical, although the epitopes targeted by the monoclonal anti-APO-l and anti-Fas 1. Abbreviations used in this paper: APO-1, apoptosis-I; ESR, erythrocyte sedimentation rate; PSS, primary Sjdgren's syndrome; SAC, Staphylococcus aureus Cowan strain 1; SLEDAI, SLE disease activity index. antibodies have not been mapped. The precise role(s) ofAPO-1 / Fas (hereafter referred to as APO-1 ) in immune regulation is not yet defined, but high levels of receptor expression in double-positive thymocytes (5) (the stage at which negative selection occurs) and in activated peripheral lymphocytes (1, (5) (6) (7) suggest that APO-I plays a role in thymic selection as well as in peripheral tolerance.
Three apparently independent mutations involving the APO-1 receptor or its putative ligand have resulted in a lupuslike disease in different mouse strains (8) (9) (10) . Although the massive lymphadenopathy which accompanies lupus in these strains is not typical of human SLE, individual cases resembling the murine disease have been reported ( 1 1), and doublenegative T cells have been implicated in the generation ofanti-DNA antibodies in SLE ( 12) . Furthermore, there is clear evidence that background genes influence the immunological abnormalities and clinical expression induced by the lpr gene ( 13) and that mild features ofautoimmunity may be observed in certain mouse strains heterozygous for the APO-1 gene mutation ( 14) . To explore the possibility that an abnormality of APO-1 may influence expression of SLE in humans, we analyzed the level of APO-1 receptor expression as well as the ability ofthe receptor to be upregulated and to signal apoptosis in the peripheral blood lymphocytes of SLE patients.
Methods
Patients. PBMC were obtained from the following groups (numbers in parentheses): SLE (23), RA (9), primary Sjbgren's syndrome (PSS) (6) , and normal individuals. All SLE and RA patients fulfilled the American College of Rheumatology criteria for these diseases (15, 16) . PSS patients had keratoconjunctivitis sicca, xerostomia, and a positive lip biopsy in the absence of any other known autoimmune disease as described previously (17) . Patients were selected randomly from the outpatient clinics at The Hospital for Special Surgery, except that patients taking cytotoxic drugs were excluded from the study. SLE disease activity was assessed by the SLE disease activity index (SLEDAI) (18) . To ensure that daily variations did not introduce systematic errors in the data, patient and control PBMC were paired and studied on the same day under the same conditions.
Flow cytometry analysis and antibodies. PBMC were isolated from peripheral blood by Ficoll-Hypaque centrifugation as described previously (19) . The following mAbs (and their antigen specificity) were used for staining: anti-APO-l (APO-I /Fas) (1); OKT3 (CD3) (20) ; 2H4-RDI (CD45RA) (21); 4B4-RDI (CDw29) (22) ; B4-RDI (CD19) (23); Leu-3a (CD4) (24) ; and Leu-2a (CD8) (24 (19) . APO-I expression on PBMC was detected by incubation of the cells with saturating amounts of anti-APO-l or the isotype control mAb followed by FITC goat anti-mouse IgG. APO-1 expression was quantified by analyzing at least 5,000 cells on the flow cytometer using the histogram obtained with the isotype control mAb to define the negative marker. Dead cells and debris were excluded from analysis by selective gating based on anterior and right angle scatter, and data were displayed on a log scale of increasing green or red fluorescence intensity. Two-color staining was performed as above except that both phycoerythrin-and FITC-conjugated second antibodies were used.
Lymphocyte culture and activation in vitro. PBMC were cultured (2 X 106 cells/ml) in complete medium comprising RPMI 1640 medium supplemented with 10% FCS (both from JRH Biosciences, Lenexa, KS), 2 mM L-glutamine, 100 U/ml penicillin, 100 gg/ml streptomycin, and 0.25 tug/ml amphotericin B in 24-well, flat-bottomed plates (Falcon Labware, Becton Dickinson & Co., Lincoln Park, NJ). The cells were maintained for up to 6 d at 370C in a humidified atmosphere in 5% CO2. The following were used for T cell activation: anti-CD3 ( 1:5,000 dilution of ascites), and recombinant human IL-2 ( 100 IU/ ml) (provided by Maurice Gately, Hoffmann-La Roche Inc., Nutley, NJ) or PHA (10 gg/ml). B cells were isolated by negative selection as described (25) . Briefly, T cells were depleted by rosetting with neuraminidase-treated sheep red blood cells followed by removal of residual cells with anti-CD3-coated magnetic beads. Flow cytometry analysis revealed < 5% T cell contamination of the resulting B cell population. Since Staphylococcus aureus Cowan strain 1 (SAC) and IL-2 have previously been shown to upregulate APO-1 expression (26), 2 X 106 B cells/well were activated by incubation with 0.02% (final concentration) heat-killed SAC (Calbiochem-Nova biochem, San Diego, CA) in the presence of IL-2 (100 IU/ml).
Apoptosis induction and assays. After the isolation ofthe cells or at varying time points after initiation of the cultures 2 x 106 cells were cultured together with 1 ig/ml of either IgG3 anti-APO-I or the isotype control mAb together with the affinity-purified rabbit anti-mouse IgG (0.8 Atg/ml) to optimize cross-linking as described (27) . Cultures were continued for an additional 12 h after which cell viability was determined by trypan blue exclusion and [3H]thymidine incorporation. Qualitative analysis ofapoptosis was performed by a minor modification of the DNA fragmentation assay (28) . Briefly, 2 x 106 cells were lysed in a buffer containing 10 mM Tris, pH 7.4, 5 mM EDTA, and 0.5% sarkosyl. Protein and RNA were digested with proteinase K and DNase-free RNase, respectively, and the DNA was extracted with phenol/chloroform. The DNA was analyzed by electrophoresis on a 2% agarose gel and was stained with ethidium bromide.
Serology. The erythrocyte sedimentation rate (ESR) was determined by the Westergren method. Antinuclear antibody levels were quantified on Hep-2-coated dipsticks (BioWhittaker, Inc., Walkersville, MD) using a fluorimeter (International Diagnostic Technologies, Santa Clara, CA). Anti-DNA antibodies were quantified using slides coated with Crithidia lucilae (Wampole Laboratories, Cranbury, NJ) and were measured on a visual scale from 0 to 4+.
Statistical analysis. Differences between the means were compared by Student's t test (for parametric data) or by the Mann-Whitney rank sum test (for nonparametric data). Correlations were analyzed by linear regression (for parametric data) or by the Spearman rank correlation coefficient (for nonparametric data).
Results
APO-J expression on freshly obtained PBMC. To minimize any day to day variation in flow cytometry analysis of APO-' expression, the percentage ofcells expressing APO-1 in the patient population was expressed as a subtraction index (APO-1 expression on the patient's cells -APO-1 expression on the normal control's cells). As shown in Fig. 1 tained from SLE patients (9±1 1) compared with normal controls (by definition, 0) (P < 0.001 ). When the percentage of cells expressing APO-1 was compared directly, the differences were also significant (SLE, 34±17 and normal controls, 25+13
[ P < 0.001 ]). Increased expression of APO-1 was also noted in patients with RA and PSS compared with normal controls, although the difference between PSS and normal controls was borderline (presumably because of the small numbers of patients tested) (Fig. 1 ).
Since APO-1 expression has been shown to be increased on activated lymphocytes ( 1, (5) (6) (7) , and see below), correlations between the percentage of cells expressing APO-1 and a predominantly clinical index (the SLEDAI) as well as between individual serological indices of disease activity were examined. As shown in Fig. 2 , no significant correlations between APO-1 expression and either clinical or serologic parameters of disease activity were observed (P > 0.05 for all analyses).
APO-J expression on lymphocyte populations. To determine which lymphocyte populations accounted for the increase in APO-1 expression, two-color flow cytometry with anti-APO-1 and mAbs specific for T (anti-CD3) or B (anti-CD19) cells was performed. As shown in Table I , a higher proportion of SLE T cells (46±14) compared with B cells (22±12) expressed APO-1. As observed for whole PBMC, the percentages ofSLE T and B cells expressing APO-1 were significantly greater than those observed in normal controls (P <0.05). To define which T cell subpopulations expressed APO-1, two-color flow cytometry was performed with anti-APO-1 and mAbs specific for either CD4, CD8, CD45, or CD29. As shown in Table I , APO-1 was expressed on both CD4+ and CD8+ T cells, but the percentage of cells expressing APO-1 was relatively greater for CD8+ compared with CD4 + cells (2.2 vs 1.5 times the normal controls, respectively). As also shown in Table I cell ( Fig. 3 A) or B cell activation (Fig. 3 B) , APO-I expression increased to > 90% in both SLE and control cells. No significant differences between SLE and controls were observed with respect to the kinetics or intensity ofAPO-1 cell-surface expression, or to the percentage of APO-l-positive cells after activation (Fig. 3) . Similar findings were observed when SLE T cells were activated with PHA (not shown). Induction of lymphocyte apoptosis. Recent studies have shown that, although peripheral T cells from normal individ- 30) . To determine whether humans with SLE have a defect in APO-I expression, regulation, or function, we quantified these parameters in patients with SLE and other systemic autoimmune diseases. In contrast to MRL/ lpr mice (5, 8) , the percentage of PBMC expressing APO-1 was significantly higher in SLE compared with normal controls. Increased expression was evident in B and T lymphocytes and in both ofthe major T cell subpopulations, CD4 and CD8. Since APO-1 is upregulated after in vitro activation of lymphocytes by mitogens or antigen receptor ligation ( 1, 5-7) and increased APO-1 expression was also observed in other systemic autoimmune disorders, the increase in expression in patients with SLE most likely reflects in vivo lymphocyte activation. In normal individ- uals the CD45RA and CD45RO antigens mark naive and memory (previously activated) T cells, respectively ( 31 ). However, despite evidence for T cell activation in SLE, some T cell activation markers (e.g., MHC class II and the fl-I integrin, CD29)
are increased whereas others (e.g., the IL-2 receptor and CD45RO) are not (for review see reference 32). As has been observed in normal individuals (33), APO-1 expression was detected almost exclusively in the (previously) activated T cell subset in SLE patients, thus supporting the concept that the increased APO-1 expression reflects lymphocyte activation. However, the lack of significant correlations with the composite index ofdisease activity, the SLEDAI, or with other serological parameters of activity indicates that the relationship between APO-1 expression and lymphocyte activation is complex.
Whereas previous studies of SLE T cells have shown that MHC class II is preferentially expressed on CD4+ T cells (34, Fig. 4 , and the released DNA isolated by phenol/chloroform extraction (28) . The DNA was subjected to electrophoresis on a 2% agarose gel, was stained with ethidium bromide, and was photographed using a videoimager as described (44) . DNA released from the lymphocytes incubated with either the control (lanes I and 2) or anti-APO-I (lanes 3 Since the majority ofSLE patients had normal or increased levels of APO-1, we examined the ability of SLE lymphocytes to upregulate APO-1 expression and to signal cell death. No defect could be detected in APO-1 expression after mitogen or receptor stimulation of SLE lymphocytes, although the stimuli and conditions for in vitro testing were not exhaustive. Similarly, SLE T lymphocytes could be induced to undergo apoptosis after activation and exposure to the anti-APO- 1 antibody as has been observed in normal lymphocytes (6, 7) . Although these findings do not exclude a role for APO-1 in the etiology of SLE, they suggest that defects in the receptor and the signaling pathway are not common features in SLE patients and that the pathway for anti-APO-l-mediated apoptosis is intact in the patients tested. These findings do not address whether the 38) . Although the lymphopenia may be explained, in part, by antilymphocyte autoantibodies, a partial depletion of T cells has been observed in the absence of detectable anti-T cell antibodies (39) . Recently, it has been shown that both CD4+ and CD8+ T cells from patients with AIDS are abnormally sensitive to activation-induced apoptosis (40, 41) , and it has been suggested that this phenomenon may be partly responsible for lymphopenia in this disease (40, 41 ) . Since the APO-1 pathway appears to be functional in SLE lymphocytes activated in vitro, it is possible that the increased expression of APO-1 results in enhanced susceptibility to apoptosis and subsequent lymphopenia in vivo. However, the failure to induce apoptosis of freshly isolated SLE PBMC or ofB cells indicates that, ifAPO-l is responsible for lymphopenia in SLE, apoptotic cells are rapidly removed in vivo. How autoantibodies, lymphokines, or possible virus infection (40) (41) (42) contribute to the balance ofactivation, survival, and death of SLE lymphocyte populations, and the roles of other molecules controlling apoptosis (43) , remain vitally important areas for further investigation.
